Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells

Laboratory Investigation

Volumn 89, Issue 11, 2009, Pages 1229-1242

  Bambang, I Fon ^a   Xu, Songci ^a   Zhou, Jianbiao ^b   Salto Tellez, Manuel ^a   Sethi, Sunil K ^a,c   Zhang, Daohai ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Cell cycle arrest; E cadherin; Endoplasmic reticulum protein 29; Epithelial mesenchymal transition; Tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLASMINOGEN ACTIVATOR; PROTEIN KINASE SYK; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN; VIMENTIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; MESODERM; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

EID: 70350625338     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.87     Document Type: Article

References (47)

1. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353: 793-802. (Pubitemid 41215488)
2. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999;91:80-85.
3. Schardt JA, Meyer M, Hartmann CH, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005;8:227-239.
4. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-846.
5. Naumov GN, Townson JL, MacDonald IC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003;82:199-206.
6. Aguirre-Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
7. Donald E, White DE, Kurpios NA, et al. Targeted disruption of b1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer cell 2004;6:159-170.
8. Aguirre-Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002;21:2513-2524.
9. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006;5:1799-1807.
10. Bulavin DV, Fornace AJ. P38 MAPK kinase's emerging rile as a tumor suppressor. Adv Cancer Res 2004;92:95-118.
11. Ranganathan AC, Zhang L, Adam AP, et al. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006;66:1702-1711.
12. Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol 2006;38:317-332.
13. Brewer JW, Diehl JA. PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proc Natl Acad Sci USA 2000;97:12625-12630.
14. Ranganathan AC, Adam AP, Zhang L, et al. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther 2006;5:729-735.
15. Sequeira SJ, Ranganathan AC, Adam AP, et al. Inhibition of proliferation by PERK regulates mammary acinar morphogenesis and tumor formation. PLoS ONE 2007;2:e615.
16. Demmer J, Zhou C, Hubbard MJ. Molecular cloning of ERp29, a novel and widely expressed resident of the endoplasmic reticulum. FEBS Lett 1997;402:145-150.
17. Mkrtchian S, Fang C, Hellman U. A stress-inducible rat liver endoplasmic reticulum protein, ERp29. Eur J Biochem 1998;251: 304-313.
18. Mkrtchian S, Sandalova T. ERp29, an unusual redox-inactive member of the thioredoxin family. Antioxid Redox Signal 2006;8: 325-337.
19. Sargsyan E, Baryshev M, Szekely L, et al. Identification of ERp29, an endoplasmic reticulum lumenal protein, as a new member of the thyroglobulin folding complex. J Biol Chem 2002;277:17009-17015.
20. Zhang B, Wang M, Yang Y, et al. ERp29 is a radiation-responsive gene in IEC-6 cell. J Radiat Res (Tokyo) 2008;49:587-596.
21. Dukes AA, Van Laar VS, Cascio M, et al. Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J Neurochem 2008;106:333-346.
22. Myung JK, Afjehi-Sadat L, Felizardo-Cabatic M, et al. Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci 2004;2:8.
23. Cheretis C, Dietrich F, Chatzistamou I, et al. Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma. Am J Dermatopathol 2006;28:410-412.
24. Shnyder SD, Mangum JE, Hubbard MJ. Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer. J Proteome Res 2008;7:3364-3372.
25. Mkrtchian S, Baryshev M, Sargsyan E, et al. ERp29, an endoplasmic reticulum secretion factor is involved in the growth of breast tumor xenografts. Mol Carcinog 2008;47:886-892.
26. Bambang IF, Lu D, Li H, et al. Cytokeratin 19 regulates endoplasmic reticulum stress and inhibits ERp29 expression via p38/XBP-1 signaling in breast cancer cells. Exp Cell Res 2009;315:1964-1974.
27. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod. Pathol. 2003;16:79-84.
28. Mukhopadhyay R, Theriault RL, Price JE. Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clin Exp Metastasis 1999;17:325-332.
29. Barkan D, Kleinman H, Simmons JL, et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 2008;68:6241-6250.
30. Kang Y, Massague J. Epithelial-mesenchymal transition: twist in development and metastasis. Cell 2004;118:277-279.
31. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer 2002;2:442-454.
32. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001;15:50-65.
33. Larue L, Bellacosa A. Epithelial-mesenchymal transitions in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005;24:7443-7454.
34. Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition and activated extracellular signal-regulated kinase (p-ERK) in surgically dissected pancreatic cancer. Ann Surg Oncol. 2007;14:3527-3533.
35. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006;6:45-54.
36. Raught B, Gingras AC, James A, et al. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 1996;56:4382-4386.
37. Lovat PE, Corazzari M, Armstrong JL, et al. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 2008;68:5363-5369.
38. Huang S, Ingber DE. Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Exp Cell Res 2000;261:91-103.
39. Perez-Moreno M, Jamora C, Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell 2003;112:535-548.
40. Lombaerts M, van Wezel T, Philippo K, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006;94:661-671.
41. Baryshev M, Sargsyan E, Mkrtchian S. ERp29 is an essential endoplasmic reticulum factor regulating secretion of thyroglobulin. Biochem Biophys Res Commun 2006;340:617-624. (Pubitemid 43021791)
42. Garćia-Higuera I, Manchado E, Dubus P, et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol 2008;10:802-811.
43. Coopman PJ, Mueller SC. The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett 2006;241: 159-173.
44. Gondi CS, Lakka SS, Dinh DH, et al. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007;13: 4051-4060.
45. Lee EJ, Whang JH, Jeon NK, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Ann NY Acad Sci 2007;1095:113-128.
46. Li Q, Mattingly R. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP Kinase activation in Ras-transformed breast epithelial cells. Neoplasia 2008;10:1444-1458.
47. Vantaggiato C, Formentini I, Bondanza A, et al. ERK1 and ERK2 motogen-activated protein kinase affect Ras-dependent cell signaling differentially. J Biol 2006;5:14.